HighTower Advisors’s Altimmune ALT Stock Holding History

HighTower Advisors’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,800	Closed	-$10.3K	–	3818
2025 Q2	$10.3K	Sell	10,800 -8,100	-43%	-$43.8K	﹤0.01%	3644
2025 Q1	$19K	Sell	18,900 -15,700	-45%	-$99.5K	﹤0.01%	3522
2024 Q4	$78.3K	Buy	34,600 +12,600	+57%	+$96.3K	﹤0.01%	3412
2024 Q3	$19.7K	Buy	22,000 +14,000	+175%	+$94.8K	﹤0.01%	3513
2024 Q2	$14.4K	Buy	+8,000	New	+$59K	﹤0.01%	3421

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HighTower Advisors's ALT Position: Q4 2025 in Review

HighTower Advisors sold out of Altimmune (ALT) in Q4 2025, closing a stake of 4,909 shares — an estimated $18.5K sold.

HighTower Advisors first reported a position in ALT in Q2 2024 and held it in 6 quarters. The position peaked at $39K in Q2 2024. 181 funds tracked by Wall St. Rank hold ALT as of Q4 2025.

HighTower Advisors reported no remaining Altimmune position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 4,909 Altimmune shares in Q4 2025, an estimated $18.5K.
HighTower Advisors first reported a position in Altimmune in Q2 2024 and held it in 6 quarters.
HighTower Advisors's Altimmune position peaked at $39K in Q2 2024.
181 funds tracked by Wall St. Rank held Altimmune as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.